3rd Quarter - Report

NVG, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues; S. 771 Improving Access to Affordable Prescription Drugs Act; S. 637 Creating Transparency to Have Drug Rebates Unlocked Act of 2017; H. 1628 American Health Care Act of 2017; H. 2430 FDA Reauthorization Act of 2017 - PDUFA; S. 934 FDA Reauthorization Act of 2017 - PDUFA; H.R. 1231/S. 456 - Research to Accelerate Cures and Equity for Children Act

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
PATRICIA GRIFFIN —
ANDREA LARUE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 771 (115th), H.R. 1231 (115th), S. 456 (115th), S. 637 (115th), S. 934 (115th)

Copyright/Patent/Trademark CPT

Intellectual property and potential changes to the patent system, generally

LobbyistCovered position, as disclosed
ANDREA LARUE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.